Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Stenke

Showing results (21-30 of 53) with videos related to

Pageof 6
Sort By:
European Journal of Haematology|August 1, 1992
Extramedullary progression of multiple myeloma following GM-CSF treatment--grounds for caution?F Celsing, R Hast, L Stenke, et al.
European Journal of Haematology|April 1, 1997
Differences in cell lineage involvement between MDS-AML and de novo AML studied by fluorescence in situ hybridization in combination with morphologyP Bernell, I Arvidsson, R Hast, et al.
British Journal of Haematology|July 23, 1998
Novel enzymatic abnormalities in AML and CML in blast crisis: elevated leucocyte leukotriene C4 synthase activity paralleled by deficient leukotriene biosynthesis from endogenous substrateL Stenke, M Sjölinder, T D Miale, et al.
Leukemia Research|August 1, 1996
A sequential erythropoietin and GM-CSF schedule offers clinical benefits in the treatment of anaemia in myelodysplastic syndromesP Bernell, L Stenke, J Wallvik, et al.
Anticancer Research|May 1, 1990
Tumor necrosis factor-alpha and interferon-gamma in serum of multiple myeloma patientsP Pisa, L Stenke, P Bernell, et al.
Annals of Clinical and Laboratory Science|March 1, 1981
Changes in urine polyamines in childhood leukemiasA Garnica, T Benton, P Slanina, et al.
Biochemical and Biophysical Research Communications|October 15, 1991
Formation and proliferative effects of lipoxins in human bone marrowL Stenke, M Mansour, C Edenius, et al.
Leukemia|September 30, 2006
A novel Bcr-Abl splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinibF X Gruber, H Hjorth-Hansen, I Mikkola, et al.
Hematological Oncology|May 1, 1991
Increase of serum interleukin-2 and regression of myeloma after rhGM-CSF treatment of drug induced bone marrow aplasiaP Bernell, P Pisa, R Hast, et al.
Lakartidningen|June 16, 1993
[Improved chances to cure hematologic diseases. The status of resources and organization of hematologic care]R Hast, M Hedenus, P Ljungman, et al.
Pageof 6

Showing results (21-30 of 53) with videos related to

Sort By:
Pageof 6
European Journal of Haematology|August 1, 1992
Extramedullary progression of multiple myeloma following GM-CSF treatment--grounds for caution?F Celsing, R Hast, L Stenke, et al.
European Journal of Haematology|April 1, 1997
Differences in cell lineage involvement between MDS-AML and de novo AML studied by fluorescence in situ hybridization in combination with morphologyP Bernell, I Arvidsson, R Hast, et al.
British Journal of Haematology|July 23, 1998
Novel enzymatic abnormalities in AML and CML in blast crisis: elevated leucocyte leukotriene C4 synthase activity paralleled by deficient leukotriene biosynthesis from endogenous substrateL Stenke, M Sjölinder, T D Miale, et al.
Leukemia Research|August 1, 1996
A sequential erythropoietin and GM-CSF schedule offers clinical benefits in the treatment of anaemia in myelodysplastic syndromesP Bernell, L Stenke, J Wallvik, et al.
Anticancer Research|May 1, 1990
Tumor necrosis factor-alpha and interferon-gamma in serum of multiple myeloma patientsP Pisa, L Stenke, P Bernell, et al.
Annals of Clinical and Laboratory Science|March 1, 1981
Changes in urine polyamines in childhood leukemiasA Garnica, T Benton, P Slanina, et al.
Biochemical and Biophysical Research Communications|October 15, 1991
Formation and proliferative effects of lipoxins in human bone marrowL Stenke, M Mansour, C Edenius, et al.
Leukemia|September 30, 2006
A novel Bcr-Abl splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinibF X Gruber, H Hjorth-Hansen, I Mikkola, et al.
Hematological Oncology|May 1, 1991
Increase of serum interleukin-2 and regression of myeloma after rhGM-CSF treatment of drug induced bone marrow aplasiaP Bernell, P Pisa, R Hast, et al.
Lakartidningen|June 16, 1993
[Improved chances to cure hematologic diseases. The status of resources and organization of hematologic care]R Hast, M Hedenus, P Ljungman, et al.
Pageof 6